Physician profile
Claudio A Rivera
NPI 1144594045
$1,759.89
in general payments reported to CMS, 2019-2025
17 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $307 · 2021: $214 · 2022: $365 · 2023: $168 · 2024: $183 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670 · Gift: $20.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.20 |
| Gift | $20.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $695.13 | 2020-2025 | Viberzi, Linzess, Rinvoq |
| Braintree Laboratories, INC. | $429.46 | 2019-2023 | Suflave |
| Gilead Sciences, INC. | $200.54 | 2021-2022 | |
| Janssen Biotech, INC. | $80.50 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $58.13 | 2024-2025 | Entyvio |
| Madrigal Pharmaceuticals | $45.00 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $44.56 | 2019 | |
| Phathom Pharmaceuticals, INC. | $27.96 | 2024 | Voquezna |
| Lilly USA, LLC | $27.81 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $25.09 | 2024 | Dupixent |
| Sun Pharmaceutical Industries INC. | $22.97 | 2021 | |
| Redhill Biopharma INC. | $20.87 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.01 | 2023 | Trulance |
| Lundbeck LLC | $18.43 | 2024 | Vyepti |
| Novo Nordisk INC | $18.19 | 2025 | Wegovy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.17 | 2019 | |
| Ardelyx, INC. | $13.07 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudio Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.